Crinetics Pharmaceuticals, Inc. Financial Statements — CRNX

Income Statement	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y
Sales/Revenue/Turnover	- -	- -	- -	- -	- -	1	5	4	1
+ Sales & Services Revenue	- -	- -	- -	- -	- -	1	5	4	1
- Cost of Revenue	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Cost of Goods & Services	- -	- -	- -	- -	- -	- -	- -	- -	- -
Gross Profit	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other Operating Income	- -	- -	- -	- -	- -	-1	-5	-4	-1
- Operating Expenses	6	9	29	54	75	109	173	227	340
+ Selling, General & Admin	2	2	7	14	18	25	42	58	100
+ Research & Development	5	9	24	42	57	84	130	169	240
+ Other Operating Expense	-1	-2	-2	-1	- -	- -	- -	- -	- -
Operating Income (Loss)	-6	-9	-29	-54	-75	-108	-168	-223	-339
- Non-Operating (Income) Loss	- -	- -	-2	-3	-1	- -	-4	-8	-40
+ Interest Expense, Net	- -	- -	-2	-3	-1	- -	-4	-13	-41
+ Interest Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -
- Interest Income	- -	- -	2	3	1	- -	4	13	41
+ Other Non-Op (Income) Loss	- -	- -	- -	- -	- -	- -	- -	5	1
Pretax Income	-6	-9	-27	-50	-74	-108	-164	-215	-298
- Income Tax Expense (Benefit)	- -	- -	- -	- -	- -	- -	- -	- -	- -
- (Income) Loss from Affiliates	- -	- -	- -	- -	- -	- -	- -	- -	- -
Income (Loss) from Cont Ops	-6	-9	-27	-50	-74	-108	-164	-215	-298
- Net Extraordinary Losses (Gains)	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Discontinued Operations	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Extraord. & Accounting Changes	- -	- -	- -	- -	- -	- -	- -	- -	- -
Income (Loss) Incl. MI	-6	-9	-27	-50	-74	-108	-164	-215	-298
- Minority Interest	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	-6	-9	-27	-50	-74	-108	-164	-215	-298
- Preferred Dividends	- -	- -	- -	- -	- -	- -	- -	- -	- -
- Other Adjustments	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income Avail to Common, GAAP	-6	-9	-27	-50	-74	-108	-164	-215	-298
Basic Weighted Avg Shares	14	14	12	24	30	38	52	58	81
Basic EPS, GAAP	-0.43	-0.66	-2.23	-2.09	-2.42	-2.8	-3.15	-3.69	-3.69
Basic EPS from Cont Ops	-0.43	-0.66	-2.23	-2.09	-2.42	-2.8	-3.15	-3.69	-3.69
Diluted Weighted Avg Shares	14	14	12	24	30	38	52	58	81
Diluted EPS, GAAP	-0.43	-0.66	-2.23	-2.09	-2.42	-2.8	-3.15	-3.69	-3.69
Diluted EPS from Cont Ops	-0.43	-0.66	-2.23	-2.09	-2.42	-2.8	-3.15	-3.69	-3.69
EBITDA	-6	-9	-28	-53	-74	-107	-167	-222	-336
EBITDA Margin (%)	- -	- -	- -	- -	- -	-9,905.38	-3,523.31	-5,519.81	-32,345.43
EBITA	-6	-9	-29	-54	-75	-108	-168	-223	-339
EBIT	-6	-9	-29	-54	-75	-108	-168	-223	-339
Gross Margin (%)	- -	- -	- -	- -	- -	100	100	100	100
Operating Margin (%)	- -	- -	- -	- -	- -	-9,990.91	-3,544.06	-5,547.17	-32,613.47
Profit Margin (%)	- -	- -	- -	- -	- -	-9,985.25	-3,460.38	-5,345.85	-28,720.69
Sales per Employee	- -	- -	- -	- -	- -	- -	- -	- -	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -
Depreciation Expense	- -	- -	- -	1	1	1	1	1	3

Balance Sheet	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y
Total Current Assets	12	15	167	123	177	345	345	574	1,375
+ Cash, Cash Equivalents & STI	12	14	164	118	171	334	334	559	1,354
+ Cash & Cash Equivalents	12	14	45	40	93	201	33	55	265
+ ST Investments	- -	- -	119	78	78	133	302	504	1,090
+ Accounts & Notes Receiv	- -	1	2	1	2	2	3	9	8
+ Accounts Receivable, Net	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Notes Receivable, Net	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Loans Receivable, Net	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other Receivable, Net	- -	1	2	1	2	2	3	9	8
+ Inventories	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Raw Materials	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Work In Process	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Finished Goods	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Inventory Adjustments	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other Inventory	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other ST Assets	- -	- -	1	4	5	9	8	6	13
+ Misc ST Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Prepaid Expenses	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ ST Derivative & Hedging Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ ST Assets Held-for-Sale	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ ST Deferred Tax Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Noncurrent Assets	- -	- -	5	7	6	6	7	61	59
+ Property, Plant & Equip, Net	- -	- -	4	6	5	5	5	57	56
+ Property, Plant & Equip	- -	1	5	8	8	8	9	62	63
- Accumulated Depreciation	- -	- -	1	2	3	3	4	5	8
+ LT Investments & Receivables	- -	- -	- -	- -	- -	1	- -	- -	- -
+ LT Investments	- -	- -	- -	- -	- -	1	- -	- -	- -
+ LT Receivables	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other LT Assets	- -	- -	- -	1	1	1	2	3	4
+ Total Intangible Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Goodwill	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other Intangible Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ LT Deferred Tax Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ LT Derivative & Hedging Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Misc LT Assets	- -	- -	- -	1	1	1	2	3	4
Total Assets	13	16	171	130	183	351	352	635	1,435
+ Payables & Accruals	1	1	5	5	6	8	15	23	21
+ Accounts Payable	- -	- -	2	3	3	3	7	7	6
+ Accrued Taxes	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Interest & Dividends Payable	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other Payables & Accruals	- -	- -	4	3	2	5	8	17	16
+ ST Debt	- -	- -	- -	- -	- -	- -	1	4	7
+ ST Borrowings	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ ST Finance Leases	- -	- -	- -	- -	- -	- -	1	4	7
+ Other ST Liabilities	- -	- -	3	3	5	8	11	17	31
+ Deferred Revenue	- -	- -	- -	- -	- -	- -	2	2	2
+ Derivatives & Hedging	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Misc ST Liabilities	- -	- -	3	3	5	8	9	15	29
Total Current Liabilities	1	1	8	8	10	16	28	44	60
+ LT Debt	- -	- -	- -	5	4	3	2	48	45
+ LT Borrowings	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ LT Finance Leases	- -	- -	- -	5	4	3	2	48	45
+ Other LT Liabilities	18	30	3	- -	- -	- -	6	5	6
+ Accrued Liabilities	- -	- -	3	- -	- -	- -	6	5	5
+ Pension Liabilities	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Deferred Revenue	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Derivatives & Hedging	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Misc LT Liabilities	18	30	- -	- -	- -	- -	- -	- -	1
Total Noncurrent Liabilities	18	30	3	5	4	3	8	52	50
Total Liabilities	19	31	11	13	15	19	36	96	110
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Share Capital & APIC	1	1	407	211	337	608	759	1,192	2,276
+ Common Stock	- -	- -	204	211	337	608	759	1,192	2,276
+ Additional Paid in Capital	1	1	204	- -	- -	- -	- -	- -	- -
- Treasury Stock	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Retained Earnings	-7	-16	-43	-94	-168	-275	-439	-654	-952
+ Other Equity	- -	- -	- -	- -	- -	- -	-4	1	1
Equity Before Minority Interest	-6	-15	160	117	169	332	316	539	1,325
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	-6	-15	160	117	169	332	316	539	1,325
Total Liabilities & Equity	13	16	171	130	183	351	352	635	1,435
Shares Outstanding	22	22	24	24	33	48	54	68	93
Capital Leases - Total	- -	- -	- -	5	4	3	3	52	52
Net Debt	-12	-14	-45	-40	-93	-201	-33	-55	-265
Net Debt to Equity	192.46	94.47	-28.07	-34.43	-55.11	-60.46	-10.33	-10.18	-19.97
Tangible Common Equity Ratio	-49.24	-96.31	93.47	89.85	92.08	94.57	89.82	84.85	92.35
Current Ratio	13.89	16.91	21.03	14.79	16.92	21.55	12.45	13.07	23.04
Cash Conversion Cycle	- -	- -	- -	- -	- -	- -	- -	- -	- -
Number of Employees	- -	- -	- -	- -	- -	- -	- -	- -	- -

Cash Flow Statement	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y
+ Net Income	-6	-9	-27	-50	-74	-108	-164	-215	-298
+ Depreciation & Amortization	- -	- -	- -	1	1	1	1	1	3
+ Non-Cash Items	- -	- -	2	5	10	17	29	39	58
+ Stock-Based Compensation	- -	- -	2	6	10	17	28	41	69
+ Deferred Income Taxes	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Asset Impairment Charge	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other Non-Cash Adj	- -	- -	- -	-1	- -	- -	1	-2	-11
+ Chg in Non-Cash Work Cap	- -	-1	5	-2	- -	1	19	8	12
+ (Inc) Dec in Accts Receiv	- -	- -	- -	- -	3	6	11	15	18
+ (Inc) Dec in Inventories	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ (Inc) Dec in Prepaid Assets	- -	-1	-2	-2	-2	-4	- -	-5	-6
+ Inc (Dec) in Accts Payable	- -	- -	7	1	3	6	- -	- -	- -
+ Inc (Dec) in Other	- -	- -	- -	-1	-3	-7	7	-2	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash from Operating Activities	-5	-9	-19	-46	-62	-89	-115	-166	-226
+ Change in Fixed & Intang	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Disp in Fixed & Intang	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Disp of Fixed Prod Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Disp of Intangible Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Acq of Fixed & Intang	- -	- -	-1	- -	- -	- -	-2	-5	-4
+ Acq of Fixed Prod Assets	- -	- -	-1	- -	- -	- -	-2	-5	-4
+ Acq of Intangible Assets	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Net Change in LT Investment	- -	- -	-118	42	- -	-56	-172	-196	-571
+ Dec in LT Investment	- -	- -	- -	150	136	69	157	337	576
+ Inc in LT Investment	- -	- -	-118	-108	-136	-125	-330	-533	-1,147
+ Net Cash From Acq & Div	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Cash from Divestitures	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Cash for Acq of Subs	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Cash for JVs	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other Investing Activities	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash from Investing Activities	- -	- -	-119	42	- -	-56	-174	-200	-575
+ Dividends Paid	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Net Cash From Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Cash From Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Repayments of Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Cash (Repurchase) of Equity	- -	- -	106	- -	114	250	117	369	970
+ Increase in Capital Stock	- -	- -	106	- -	114	250	117	369	970
+ Decrease in Capital Stock	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Other Financing Activities	- -	12	64	- -	- -	3	5	20	40
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash from Financing Activities	- -	12	170	- -	115	253	122	389	1,010
Effect of Foreign Exchange Rates	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Changes in Cash	-6	2	31	-5	53	108	-167	22	210
Capital Expenditures	- -	- -	-1	- -	- -	- -	-2	-5	-4
EBITDA	-6	-9	-28	-53	-74	-107	-167	-222	-336
EBITDA Margin (%)	- -	- -	- -	- -	- -	-9,905.38	-3,523.31	-5,519.81	-32,345.43
Net Cash Paid for Acquisitions	- -	- -	- -	- -	- -	- -	- -	- -	- -
Free Cash Flow	-6	-10	-21	-47	-62	-89	-117	-171	-230
Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -
Free Cash Flow to Equity	- -	-10	-21	-47	-62	-89	-117	-171	-230
Free Cash Flow per Basic Share	-0.41	-0.7	-1.69	-1.94	-2.04	-2.32	-2.25	-2.94	-2.84
Price/Free Cash Flow	- -	- -	-19.79	-13.22	-6.95	-12.39	-8.38	-12.78	-18.6
Cash Flow to Net Income	0.91	1.04	0.72	0.92	0.84	0.82	0.7	0.78	0.76

Crinetics Pharmaceuticals, Inc.

Income Statement

Balance Sheet

Cash Flow Statement